Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

Background: We present the first report comparing early toxicity outcomes with high-dose rate brachytherapy (HDR-BT) boost upfront versus intensity modulated RT (IMRT) upfront combined with androgen deprivation therapy (ADT) as definitive management for intermediate risk or higher prostate cancer. M...

Full description

Bibliographic Details
Main Authors: Amit Roy, Randall J. Brenneman, Jacob Hogan, Justin M. Barnes, Yi Huang, Robert Morris, Sreekrishna Goddu, Michael Altman, Jose Garcia-Ramirez, Harold Li, Jacqueline E. Zoberi, Arnold Bullock, Eric Kim, Zachary Smith, Robert Figenshau, Gerald L. Andriole, Brian C. Baumann, Jeff M. Michalski, Hiram A. Gay
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Clinical and Translational Radiation Oncology
Subjects:
High-dose rate
Brachytherapy
Intensity modulated radiation therapy
Prostate cancer
Androgen deprivation therapy
Toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630821000483

Internet

http://www.sciencedirect.com/science/article/pii/S2405630821000483

Similar Items